Company Science

Día Mundial de la Zoonosis: Más del 60% de las enfermedades infecciosas humanas provienen de animales

Jul 08 2020

Los cambios sociales, ecológicos, de producción y las restricciones, cada vez mayores, en el uso de antibióticos hacen que se deba extender el empleo de vacunas animales y humanas.

La fabricación nacional de la vacuna contra la COVID-19 podría pasar por la certificación de las farmacéuticas veterinarias para fabricar vacunas de uso humano.

Algenex infografia Zoonosis FINAL 4 page 0001 scaled - AlgenexM√°s del 60% de las enfermedades infecciosas humanas, como la COVID-19, provienen de los animales; hasta el 75% de las nuevas enfermedades que han afectado a las personas en los √ļltimos 10 a√Īos se originaron en animales; y alrededor de 2,2 millones de personas mueren al a√Īo por zoonosis, datos de Animal Health Europe que cobran especial importancia en la celebraci√≥n del D√≠a Mundial de la Zoonosis de este a√Īo.

Estas cifras y las cada vez mayores restricciones de las agencias reguladoras en el uso de los antibi√≥ticos evidencian la necesidad de prevenir las enfermedades infecciosas humanas y animales de forma conjunta mediante el empleo de vacunas. La actual pandemia provocada por el virus SARS-CoV-2 ha puesto de manifiesto que Espa√Īa no cuenta con plantas de fabricaci√≥n de vacunas de uso humano, por lo que la producci√≥n nacional de la vacuna para la COVID-19 podr√≠a estar ligada a las f√°bricas de vacunas veterinarias.

De √©stas √ļltimas s√≠ hay representaci√≥n muy significativa y de alto nivel en nuestro pa√≠s y cuentan con experiencia de producci√≥n industrial. Sin embargo, requerir√°n de su adaptaci√≥n y certificaci√≥n por parte de la Agencia Espa√Īola del Medicamento para la fabricaci√≥n de vacunas de uso humano, un proceso que ya est√° en curso en algunos casos.

Seg√ļn Accurize Market Research, s√≥lo el 26% de las ventas de las compa√Ī√≠as farmac√©uticas veterinarias proviene de las vacunas y se prev√© que este mercado crezca a un ritmo anual del 6,5%, hasta alcanzar un valor aproximado de 10.000 millones de euros en 2025. Un incremento importante que tendr√° repercusiones positivas en la salud humana.

En este contexto, empresas como Algenex -biofarmac√©utica 100% espa√Īola especializada en la fabricaci√≥n de prote√≠nas para la obtenci√≥n de vacunas- cobran especial relevancia. Esta compa√Ī√≠a ha desarrollado la tecnolog√≠a CrisBio¬ģ que permite producir prote√≠nas para vacunas y otros productos biotecnol√≥gicos de manera sencilla, r√°pida y escalable frente a los complejos procesos tradicionales. ‚ÄúEsta tecnolog√≠a tiene dos ventajas clave: permite una escalabilidad lineal y pr√°cticamente ilimitada; y reduce los costes de inversi√≥n y operativos que permitir√≠a desarrollar una vacuna que pudiera implementarse en campa√Īas de vacunaci√≥n en todo el mundo, incluidos los pa√≠ses en v√≠as de desarrollo‚ÄĚ, explica el doctor Jos√© Escribano, fundador y director cient√≠fico de la compa√Ī√≠a.

‚ÄúAlgenex espera que la primera vacuna veterinaria producida en CrisBio est√© en el marcado en el 2021 tras la aprobaci√≥n por parte de la Agencia Europea del Medicamento (EMA, por sus siglas en ingl√©s). Asimismo, cuenta con otras vacunas en desarrollo contra enfermedades v√≠ricas para varias especies animales en distintas fases de desarrollo, con capacidad de llegar al mercado en los pr√≥ximos a√Īos‚ÄĚ, indica Claudia Jim√©nez, directora general de la compa√Ī√≠a.

De la salud animal a la humana

Hasta ahora, Algenex ha utilizado esta tecnolog√≠a para la fabricaci√≥n de vacunas animales. Sin embargo, ya en 2019 realiz√≥ una prueba de concepto en una variante de gripe aviar con potencial de constituir una zoonosis que podr√≠a volverse pand√©mica. La compa√Ī√≠a demostr√≥ su capacidad de fabricar un candidato a vacuna en solo dos meses y mostr√≥ la funcionalidad y la plena seguridad de esta vacuna en modelos animales. A partir de esta experiencia, Algenex eval√ļa ahora mismo posibilidades para usar CrisBio¬ģ en desarrollos enfocados a combatir pandemias como la que estamos viviendo.

En este mes de julio, Algenex trasladar√° su sede desde el Parque Cient√≠fico y Tecnol√≥gico de la Universidad Polit√©cnica de Madrid (Campus de Montegancedo, Pozuelo de Alarc√≥n) a su nueva factor√≠a len la localidad de Tres Cantos. Esta nueva factor√≠a cuenta con instalaciones para producir suficientes ant√≠genos como para formular m√°s de 50 millones de dosis vacunales al a√Īo.Algenex cuenta con amplia experiencia en el desarrollo de productos veterinarios y ha sido seleccionada como una de las 20 empresas con m√°s impacto en salud animal por las organizaciones IHS y Stonehaven Consulting en su informe publicado en marzo ‚ÄúDisruptors and Innovators 2020 Report‚ÄĚ.

Enfermedades zoonóticas

Las patologías zoonóticas son un grupo de enfermedades infecciosas que se transmiten de forma natural de los animales a los seres humanos bien por contacto directo, indirecto o por el consumo de productos derivados de los propios animales o, incluso, de su entorno. Son enfermedades frecuentes que pueden ser provocadas por virus, bacterias, parásitos y hongos.

Puedes descargar la infografía aquí

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Science Technology

Algenex obtiene financiación del CDTI para desarrollar productos contra la COVID-19

May 13 2020

La compa√Ī√≠a biotecnol√≥gica espa√Īola Algenex ha conseguido financiaci√≥n del CDTI, dependiente del Ministerio de Ciencia e Innovaci√≥n, para el desarrollo de distintos productos encaminados a luchar contra la actual pandemia de coronavirus. Esta financiaci√≥n permitir√° a la compa√Ī√≠a trabajar en el desarrollo de un candidato de vacuna contra el SARS-CoV-2 y de test diagn√≥sticos para la detecci√≥n de anticuerpos.

Claudia Jim√©nez, Directora General de Algenex, ha se√Īalado que la validaci√≥n del proyecto por el CDTI ‚Äúes una confirmaci√≥n de la madurez de Algenex y de lo prometedora que es nuestra tecnolog√≠a. Ahora que el desarrollo de las vacunas experimentales basadas en prote√≠nas del virus est√° m√°s avanzando, es momento de pensar en c√≥mo garantizar su producci√≥n industrial, considerando tanto el n√ļmero de dosis como su comercializaci√≥n a un precio asumible para que pueda ser usada en campa√Īas de vacunaci√≥n globales. Nuestra tecnolog√≠a CrisBio puede ser fundamental en este aspecto‚ÄĚ, ha se√Īalado.

Tecnología disruptiva y patentada

La compa√Ī√≠a, con sede en la Comunidad de Madrid, cuenta con una tecnolog√≠a disruptiva y patentada para producir productos biotecnol√≥gicos basados en prote√≠nas recombinantes denominada CrisBio¬ģ. CrisBio¬ģ utiliza insectos como biorreactores naturales, mediante la inoculaci√≥n robotizada de virus vectores baculovirus modificados gen√©ticamente, en las cris√°lidas de un lepid√≥ptero, la trichoplusia ni. El virus coloniza las c√©lulas vivas del insecto y √©stas comienzan a producir la prote√≠na deseada.

CrisBio¬ģ permite la producci√≥n de ant√≠genos vacunales, anticuerpos o prote√≠nas diagn√≥sticas de una forma r√°pida y con un escalado industrial lineal y pr√°cticamente ilimitado. Los costes de inversi√≥n en una factor√≠a basada en CrisBio¬ģ, as√≠ como los costes operativos de producci√≥n, son solo una fracci√≥n de aquellos requeridos en factor√≠as tradicionales basadas en biorreactores, permitiendo el acceso global a productos biotecnol√≥gicos.

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Science Technology

Algenex presents at LSX London

Feb 10 2020

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com.

Más información:

Comunicación Algenex

Mónica Bernardo
mbernardo@agenciacomma.com
Móvil + 34 610 54 40 90

Rosa Matías
rmatias@agenciacomma.com
Móvil +34 676 96 07 69

Science Technology

Bioinnovo, Algenex reinforce vaccine molecule arrangement

Dec 06 2019

Argentina’s Bioinnovo has updated its partnership with Spanish firm Algenex for the use of a molecule developed by the latter.

The renewed partnership provides Bioinnovo with the international rights to use Algenex’s APCH (antigen presenting cells homing) molecule in the field of animal health. Bioinnovo is currently evaluating and developing the application of APCH for the control of other pathogens.

Bioinnovo is a public-private company formed by the National Institute of Agricultural Technology (INTA) and domestic firm Vetanco ‚Äď both headquartered in Buenos Aires. Vetanco president Jorge Winokur told Animal Pharm the molecule will be used in other vaccines for ruminants.

The new deal follows several years of collaboration, after INTA initially began collaborating with Algenex in 2008. The original pact was designed to develop the Vedevax Block bovine diarrhea virus vaccine using the APCH molecule.

Vetanco is selling Vedevax Block in Argentina and is preparing registration dossiers for the vaccine in an extra six undisclosed countries. Mr Winokur said “advanced discussions with a major player are ongoing for the distribution in Europe and North America”.

Bioinnovo stated: “Data collected by us, regulatory agencies and third parties show protective antibody titers achieved by Vedevax Block saturate the detection capacity of conventional testing methods, representing a milestone achievement in controlling BVD in the field.”

APCH insight

The APCH molecule was first developed by a research group at Spain’s Instituto Nacional de Investigaci√≥n y Tecnolog√≠a Agraria y Alimentaria. This research group was led by Jos√© Escribano ‚Äď Algenex founder and chief scientific officer. The molecule was then licensed to Algenex.

Dr Escribano told Animal Pharm: “APCH is an antibody that recognizes the class II antigen molecule in immune cells of all animal species, including humans. When any vaccine antigen is fused to this antibody and injected into the body, it is immediately driven to the immune professional cells and generates a potent immune response. It is a molecule to boost the immune responses against subunit vaccines.

“APCH is produced as a single-chain antibody and may reduce the antigen dose delivering cellular and humoral immune responses simultaneously. It is the case of the new vaccine against bovine viral diarrhea developed with the virus protein E2 fused to APCH and produced in insect cells. APCH may be used in protein-based vaccines as well as in DNA or vectorized vaccines.”

Earlier this month, Madrid-based Algenex added another commercial license agreement with Italy’s Fatro to its roster of partnerships. This particular collaboration is for the development of an unspecified swine vaccine.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company Science Technology

Algenex and FATRO sign commercial license agreement for development of a second CrisBio¬ģ-based vaccine

Dec 02 2019

Agreement strengthens collaboration between the companies following submission of the first dossier to the European Medicines Agency (EMA) for a CrisBio¬ģ produced recombinant vaccin.

Algenex SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, and FATRO S.p.A, a leader in the field of veterinary pharmaceutical products, today announce that they have entered into a new commercial license agreement for the development of a second CrisBio¬ģ-based vaccine for a major swine indication.

This is the second commercial license agreement between the two companies. The first agreement, for the worldwide use and industrial production of a recombinant vaccine using CrisBio¬ģ technology, was signed in September 2015.

CrisBio¬ģ is Algenex‚Äô proprietary and patent protected Baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. It is a versatile and robust alternative to current bioreactor-based expression technologies and offers additional benefits including linear scalability, reduced production costs and increased productivity, reaching gram per litre yields. In October, Algenex announced the submission of a dossier to the European Medicines Agency (EMA) for a recombinant VLP vaccine produced using Algenex‚Äô proprietary CrisBio¬ģ technology . The submission is targeting a European marketing authorization via the centralized approval system. This was the first vaccine produced using Algenex‚Äô CrisBio¬ģ technology to be submitted for regulatory approval.

‚ÄúWe are delighted to have strengthened our collaboration with FATRO through this new commercial license agreement,‚ÄĚ said Dr. Jose Escribano, Founder and CSO of Algenex. ‚ÄúWe‚Äôve been working closely with FATRO since¬† 2015 and this new agreement is further validation for our proprietary CrisBio¬ģ platform and its potential to transform vaccine production in major indications in both animal and human health. We remain committed to fulfilling our vision of transforming protein production to enable universal access to biotechnology.‚ÄĚ

‚ÄúFor FATRO, CrisBio¬ģ technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products,‚ÄĚ stated Dr. Francesco Meliota, vice president responsible for IVMPs, ‚Äúand the excellent results obtained during the development of the first product further reinforced our belief in its practical potentialities, convincing us to sign this new agreement with Algenex.‚ÄĚ

Commercial and financial terms of the agreement were not disclosed.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus -based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. Algenex plans to expand the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com

About FATRO S.p.A

Founded in 1947, FATRO is a pharmaceutical company that has always concentrated its activities exclusively in the veterinary medicine sector.

The beating heart of its research laboratories and its main production plants are located in I taly. FATRO has its own subsidiary companies in Poland, Spain, Greece, Czech Republic, Argentina, Uruguay, India and exports its products to over 90 Countries. Currently, the Group employs over 700 people worldwide.

FATRO invests continuously in research in the ethical drugs and veterinary vaccines sectors, with the aim of developing new products and production technologies.

For more information, please visit Fatro.it

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Fatro
Silvana Dal Magro
President
T: +39 051 6512711
fatro@fatro.it

Company CrisBio Science Technology

Algenex adds to Fatro relationship with second vaccine license

Dec 02 2019

Spanish start-up Algenex has entered another commercial license agreement with Italy’s Fatro for development of a swine vaccine.

Fatro will use Algenex’s CrisBio baculovirus vector-mediated expression platform to develop a vaccine for a “major swine indication”.

The latest deal strengthens an existing collaboration between the two companies signed in 2015. The pre-existing partnership allowed Fatro to develop a recombinant vaccine for an undisclosed indication with the CrisBio technology. This recently culminated in the first submission of a CrisBio-based vaccine for European centralized approval.

Algenex’s platform “harnesses the power of insects to act as natural single-use bioreactors”. The Madrid-based firm claims this system is a versatile and robust alternative to current bioreactor-based expression technologies. CrisBio also offers “additional benefits including linear scalability, reduced production costs and increased productivity, reaching gram-per-liter yields”.

Dr Francesco Meliota ‚Äď vice president of immunological veterinary medicinal products at Fatro ‚Äď remarked: “For Fatro, CrisBio technology represents an important opportunity to expand its portfolio of vaccines for veterinary use with a series of highly innovative products and the excellent results obtained during the development of the first product further reinforced our belief in itspractical potentialities, convincing us to sign this new agreement with Algenex.”

Fatro ‚Äď headquartered in Bologna ‚Äď is the leading animal health business located in Italy. Established in 1947, the company works exclusively in the animal health industry. It has subsidiaries in Spain, Greece, the Czech Republic, Poland, Argentina, Uruguay and India. The firm also exports its products to over 90 countries.

Pipeline includes ASF vaccine

Algenex claims to have successfully produced over 200 molecules and gained proof-of- concept data in more than 20 vaccines in collaboration with public and private partners, including “multiple international pharmaceutical companies”.

As well as CrisBio, the company is also developing vaccine candidates using its TopBac system. This technology features in a proprietary patented expression cassette and, when incorporated into the genome of a baculovirus vector, it “significantly improves the productivity and quality of recombinant proteins produced by host cells”.

Algenex’s pipeline features three CrisBio-based vaccines that are also part of commercial partnerships with undisclosed companies. These are for rabbit hemorrhagic disease virus, porcine circovirus type 2 and African swine fever (ASF). The firm is also working on two vaccines ‚Äď for porcine circovirus type 2 (using the TopBac technology) and avian influenza (CrisBio) ‚Äď that currently require commercial partnerships.

The firm’s general manager Claudia Jim√©nez told Animal Pharm: “For ASF, we have an ongoing partnership for the development of a potential vaccine but we are also in the process of validating a rapid test that could be on the market at a substantial discount to current diagnostic kits thanks to the fact we produce the protein in CrisBio.

“In avian influenza, we are generating some pretty interesting data that could serve as proof-of-concept for flu indications and other developments, including in humans.”

While Algenex is currently focused on animal health, it intends to expand its scope into the human health sector in the future. Currently, the firm has one commercialized product ‚Äď a bovine diarrhea virus vaccine Vedevax block, which is sold in Argentina by local firm Vetanco and based on an Algenex patent.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Science Technology

First dossier with CrisBio filed to EMA

Oct 26 2019
Company Science Technology

First Algenex CrisBio¬ģ-based vaccine submitted to European Medicines Agency

Oct 15 2019

Algenex today announces that one of its industry partners has submitted a dossier to the European Medicines Agency (EMA) for a recombinant VLP vaccine produced using Algenex‚Äô proprietary CrisBio¬ģ technology. The submission is targeting a European marketing authorization via the centralized approval system. This is the first vaccine produced using Algenex‚Äô CrisBio¬ģ technology to be submitted for regulatory approval.

CrisBio¬ģ is Algenex‚Äô proprietary and patent protected baculovirus vector-mediated expression platform that harnesses the power of insects to act as natural single-use bioreactors. It is a versatile and robust alternative to current bioreactor-based expression technologies and offers additional benefits including linear scalability, reduced production costs and increased productivity, reaching gram per litre yields.

‚ÄúCrisBio¬ģ has the potential to transform recombinant protein production and this first submission to the EMA by one of our industry partners is a key milestone for Algenex,‚ÄĚ said Claudia Jim√©nez, General Manager of Algenex. ‚ÄúA potential approval would serve as regulatory validation and pave the way for future regulatory submissions for both vaccines and other biological products. We continue to work closely with our partners to deliver on our mission to be the partner of choice for the production and manufacture of protein-based products.‚ÄĚ

Download

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Company Science Technology

Algenex and Global DX sign agreement to develop and commercialize diagnostic products for the detection of African Swine Fever

May 28 2019

Algenex SL, a private biotechnology company delivering disruptive technologies for recombinant biologics production, and Global DX Ltd, a company dedicated to improving the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide, today announce that they have entered into an agreement to jointly develop and commercialize diagnostic products for the detection of African Swine Fever.

The first product to be developed will be a point-of-care rapid diagnostic test to identify pigs who have been exposed to the African Swine Fever Virus (ASFV). The agreement is the first collaboration between the two companies and provides the framework for further co-developments across a potentially wide range of diagnostic areas.

Under the terms of the agreement, Algenex will deliver the diagnostic reagents and Global DX will provide the technical expertise to develop and manufacture the point-of-care rapid diagnostic tests. Both companies will collaborate in the distribution of the final product, which is anticipated to be ready for commercialisation in Europe by the end of 2019.

African Swine Fever is a severe viral disease for which there is currently no available vaccine. It affects domestic pigs and wild boars and causes high mortality, approaching 100% in less than 10 days in acute cases. The clinical symptoms of the ASFV infection are similar to those of Classical Swine Fever, and the two diseases can only be differentiated through laboratory diagnosis.

The disease was eradicated in Europe (with the exception of Sardinia) in the 1990s via drastic control and eradication programs. Algenex’ Founder and Chief Scientific Officer, José Angel Escribano, played a role in the eradication of the virus in Europe during this time, contributing to the development of some of the OIE reference diagnostic tests. In 2007, the disease spread again out of Africa into the Caucasus, Russia and more recently into China, where it has led to the slaughter of several million pigs in an effort to control the dissemination of the virus. In 2014, the ASFV reached the eastern territories of the European Union. Latest reports imply the disease has reached a growing list of countries in the EU, Eastern Europe, the Baltics and other Asian territories aside from China, representing possibly the most serious threat that the global veterinary industry has had to face in the last decades.

‚ÄúWe are excited to be joining forces with Global DX to develop diagnostic products for the detection of the ASFV,‚ÄĚ said Claudia Jim√©nez, General Manager of Algenex. ‚ÄúBy combining Algenex‚Äô expertise in protein expression and an understanding of the ASFV through the involvement of our Founder in the previous eradication campaign, with Global DX‚Äôs diagnostic capabilities, we have the potential to play an important role in stopping the further dissemination of this highly contagious disease that is already having devastating consequences in China and across other geographies.‚ÄĚ

‚ÄúGlobal DX is very excited to partner with Algenex in the development of this rapid test. The test to be developed will constitute an important element in the battle against African Swine Fever, adding a product with a high unmet need to our growing catalogue and placing us at the forefront of innovation in veterinary diagnostics,‚ÄĚ said Andrew Shepherd, Founder and CEO of Global DX.

Download

About Algenex

Algenex is a private biotechnology company developing disruptive technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.

To date, Algenex’ work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple in ternational pharmaceutical companies. Algenex plans to expand the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex.com

About Global DX

Global DX Ltd is a private veterinary diagnostics company developing and producing high quality and innovative diagnostic solutions specialising in Rapid Test technologies. On the basis of more than 70 years of experience in the In Vitro Diagnostics industry, the company is aiming to improve the quality of animal care by facilitating accurate diagnosis for veterinarians worldwide. Building on a range of Rapid Tests for Companion Animals (Petscreen ¬ģ) and Livestock Animals (Herdscreen¬ģ) Global DX is applying Rapid Test technologies and novel test solutions for important diseases of worldwide importance.

For more information, please visit GlobalDX.com

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com

Global DX contact
Andrew Shepherd
Founder & CEO
T: +44 1259 230830
andrew.shepherd@globaldx.com

Science Technology

ALGENEX supports development of recombinant biologics with ‚ā¨4m funding round

May 25 2019

Spanish biotechnology firm Algenex has progressed to its next stage of development after securing approximately ‚ā¨4 million ($4.5 million) in investment.

About Algenex

Algenex is a private biotechnology company developing disruptive baculovirus-based technologies for the production of recombinant biologics. Algenex¬ī first two platforms, TopBac¬ģ and CrisBio¬ģ, are based on baculovirus-based expression systems and have demonstrated their capacity to transform recombinant protein production through a process that provides almost unlimited and immediate scalability of manufacturing, production flexibility, simplicity and versatility while being extremely cost efficient.
To date, Algenex‚Äô work has centred mainly on the development and production of veterinary vaccines, with > 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies. The first dossier for a veterinary vaccine produced in CrisBio¬ģ is currently being reviewed by EMA.

Algenex has now expanded the application of its proprietary and patented technologies into human health in order to fully exploit the potential of its platforms.

For more information, please visit Algenex technologies.

For further information, please contact:

Algenex
Claudia Jiménez
General Manager
T: +34 91 452 4941
cjimenez@algenex.com